Merck's relebactam dubbed qualified infectious disease product
This article was originally published in Scrip
Executive Summary
Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.
You may also be interested in...
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Merck And The 'Strange Business' Of Antibiotics
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
The latest drug development news and highlights from our US FDA Performance Tracker.